{"id":"NCT02998528","sponsor":"Bristol-Myers Squibb","briefTitle":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-04","primaryCompletion":"2021-09-08","completion":"2024-12-06","firstPosted":"2016-12-20","resultsPosted":"2022-09-28","lastUpdate":"2025-01-24"},"enrollment":505,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non Small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Vinorelbine","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["BMS-734016","Yervoy"]}],"arms":[{"label":"Platinum doublet chemotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Nivolumab plus platinum doublet chemotherapy","type":"EXPERIMENTAL"},{"label":"Nivolumab plus Ipilimumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.\n\nThis study has multiple primary endpoints.","primaryOutcome":{"measure":"Event-Free Survival (EFS)","timeFrame":"From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)","effectByArm":[{"arm":"Arm B: Platinum Doublet Chemo","deltaMin":20.8,"sd":null},{"arm":"Arm C: Nivo 360 mg + Platinum Doublet Chemo","deltaMin":31.57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0052"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":140,"countries":["United States","Argentina","Brazil","Canada","China","France","Greece","Hungary","Italy","Japan","Netherlands","Romania","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["40454642","39778121","37903504","37141544","36815433","35403841"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":111},"commonTop":["Nausea","Constipation","Anaemia","Decreased appetite","Fatigue"]}}